envafolimab + Endostar + S-1

The combination "envafolimab + Endostar + S-1" is a non-chemotherapeutic treatment regimen being investigated primarily for advanced non-small cell lung cancer (NSCLC). This combination brings together three distinct therapeutic agents with complementary mechanisms of action. ## Components of the Combination **Envafolimab** is the world's first subcutaneously injected PD-L1 immune checkpoint inhibitor. It has been approved in China for treating microsatellite instability-high (MSI-H) or DNA-mismatch repair (dMMR) solid tumors[1][3]. As an immunotherapy agent, it works by blocking the PD-L1 pathway, thereby enhancing the immune system's ability to detect and destroy cancer cells. **Endostar** is a recombinant human endostatin developed in China that functions as an anti-angiogenic agent. It exerts its effects by: - Blocking tyrosine phosphorylation of the KDR/Flk-1 receptor induced by vascular endothelial growth factor (VEGF) - Inhibiting the migration and invasion of vascular endothelial cells - Suppressing integrin and matrix metalloproteinase 2 - Inhibiting tumor growth and metastasis[1] **S-1** is an oral fluoropyrimidine anticancer drug that combines tegafur (a prodrug of 5-fluorouracil) with two modulators: gimeracil and oteracil potassium. ## Clinical Investigation The combination is being studied in a Phase 2 clinical trial (NCT05529355) for second-line treatment of advanced non-small cell lung cancer[4][5]. This trial is being conducted at Anhui Chest Hospital and began in September 2022. ## Therapeutic Rationale The rationale for combining these agents stems from their complementary mechanisms: 1. **Immunotherapy + Anti-angiogenesis Synergy**: The combination of immune checkpoint inhibitors with anti-angiogenic therapy has shown promising results in various cancers. Endostar can potentially normalize tumor vasculature, which may enhance the delivery and efficacy of immunotherapy agents like envafolimab[1][3]. 2. **Chemotherapy-Free Option**: This regimen offers a potential alternative for patients who cannot tolerate or decline traditional chemotherapy, particularly elderly patients or those concerned about toxic side effects[1][2]. 3. **Efficacy in Special Populations**: Case reports suggest this combination may be particularly beneficial for patients with advanced NSCLC characterized by low PD-L1 expression and negative driver gene mutations[1][2]. ## Safety Profile The combination therapy appears to have a favorable safety profile: - Endostar administered via continuous intravenous infusion is associated with fewer side effects compared to other anti-angiogenic drugs[1] - Envafolimab's subcutaneous administration route may improve patient compliance and quality of life compared to intravenous immunotherapy options[1][2] - Case reports indicate the combination has been well-tolerated with no notable adverse reactions in some patients[2] However, more comprehensive safety data from larger clinical trials is still needed to fully establish the safety profile of this specific three-drug combination. ## Current Development Status This combination therapy is currently in Phase 2 clinical trials for second-line treatment of advanced non-small cell lung cancer. While case reports show promising results, larger studies are needed to definitively establish its efficacy and safety profile compared to standard treatment options.